Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > NanoBio Initiates FDA Approved Clinical Trial for Adjuvanted Intranasal Influenza Vaccine

Abstract:
Phase 1 Study to Demonstrate Safety and Proof of Concept for Highly Effective, Non-Inflammatory, Nanoemulsion Adjuvant Platform Technology

NanoBio Initiates FDA Approved Clinical Trial for Adjuvanted Intranasal Influenza Vaccine

Ann Arbor, MI | Posted on April 21st, 2009

NanoBio Corp. announced today that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for the Phase 1 clinical study of NB-1008, a seasonal influenza vaccine administered via a nasal dropper. NB-1008 uses a novel nanoemulsion-based adjuvant to achieve a robust immune response using only a small fraction of the antigen required by currently available injectable vaccines. In numerous animal studies, NB-1008 has demonstrated robust mucosal, systemic and cellular immunity without inflammation or safety concerns.

The underlying technology for NB-1008 is NanoBio's NanoStatTM platform, which employs a nanoemulsion that is created through a proprietary manufacturing process. The nanoemulsion is uniquely capable of permeating the nasal mucosa, where it can load vaccine antigen into immune-presenting cells. These cells then carry the antigen to areas of the body that initiate an immune response, including the lymph nodes, thymus and spleen. NanoBio is in various stages of preclinical development for numerous other nanoemulsion-adjuvanted vaccines, including hepatitis B, pandemic influenza, RSV, HIV, pneumococcal, cancer, anthrax and smallpox.

"The initiation of this study represents a significant accomplishment for NanoBio, and enormous potential to fundamentally change vaccine development," said James R. Baker, Jr., MD, NanoBio's CEO and founder. "We have identified a unique approach to inducing immunity that involves nasal immune elements. Our NanoStat technology takes advantage of this pathway to produce a level of protective immunity not seen with currently available vaccines."

In naïve ferrets, NanoBio has shown that a single intranasal administration of NB-1008 containing two percent (2%) of the standard vaccine dose elicited robust immune responses, while a control arm with one full dose of a commonly-used injectable vaccine demonstrated no response. Seasonal influenza vaccines are often tested in ferrets as the animal species most predictive of human response to vaccination.

"There is an unmet need for new vaccine approaches that can address high risk individuals with less effective immunity, including the young and elderly. In addition, it would be a significant accomplishment to provide cross-protection against many strains of influenza virus that are not incorporated within the vaccine," commented Dr. Baker. "We are quite excited that extensive animal data using the NanoStat technology suggests it could achieve these goals. We look forward to the results of these trials to confirm these findings."

The Phase 1 trial is a randomized, controlled study in the United States involving 120 healthy human volunteers. The primary endpoints are safety and immunogenicity as determined by neutralizing serum antibodies.

About NanoBio's Vaccine Platform

NanoBio's nanoemulsion-based, intranasal vaccines have elicited robust immune responses in animals vaccinated against influenza, hepatitis B, RSV, HIV, cancer, anthrax, smallpox and other diseases. The NanoStat platform technology has demonstrated numerous potential advantages over traditional vaccines, including: the ability to generate robust mucosal, systemic and cellular immunity; antigen-sparing qualities; cross-protection against strains not included in the vaccine; ability to adjuvant multiple antigen types without inducing inflammation; thermally stabilizing the vaccine; and removing the need for needles.

####

About NanoBio Corp.
NanoBio® Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead dermatology and anti-infective product candidates include treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, molluscum contagiosum, and cystic fibrosis. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.

For more information, please click here

Contacts:
NanoBio Corp.
John Coffey
734-302-9107
Vice President, Business Development

or
Schwartz Communications
Stacey Holifield / Laura Coluci
781-684-0770

Copyright © Business Wire 2009

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Iran to Hold 3rd Int'l Engineering Materials, Metallurgy Conference October 25th, 2014

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

SUNY Polytechnic Institute Invites the Public to Attend its Popular Statewide 'NANOvember' Series of Outreach and Educational Events October 23rd, 2014

Nanomedicine

NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014

Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014

RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014

Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014

Announcements

Iran to Hold 3rd Int'l Engineering Materials, Metallurgy Conference October 25th, 2014

Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014

QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014

Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014

NanoNews-Digest
The latest news from around the world, FREE





  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE